Single nucleotide polymorphisms and genotypes of transient receptor potential ion channel and acetylcholine receptor genes from isolated B lymphocytes in myalgic encephalomyelitis/chronic fatigue syndrome patients

Sonya Marshall-Gradisnik¹,², Samantha Johnston¹,², Anu Chacko¹,², Thao Nguyen¹,², Peter Smith² and Donald Staines¹,²

Abstract

Objective: The pathomechanism of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) is unknown; however, a small subgroup of patients has shown muscarinic antibody positivity and reduced symptom presentation following anti-CD20 intervention. Given the important roles of calcium (Ca²⁺) and acetylcholine (ACh) signalling in B cell activation and potential antibody development, we aimed to identify relevant single nucleotide polymorphisms (SNPs) and genotypes in isolated B cells from CFS/ME patients.

Methods: A total of 11 CFS/ME patients (aged 31.82 ± 5.50 years) and 11 non-fatigued controls (aged 33.91 ± 5.06 years) were included. Flow cytometric protocols were used to determine B cell purity, followed by SNP and genotype analysis for 21 mammalian TRP ion channel genes and nine mammalian ACh receptor genes. SNP association and genotyping analysis were performed using ANOVA and PLINK analysis software.

¹School of Medical Science, Griffith University, Gold Coast, QLD, Australia
²The National Centre for Neuroimmunology and Emerging Diseases, Menzies Health Institute Queensland, Griffith University, Gold Coast, QLD Australia

Corresponding author:
Sonya Marshall-Gradisnik, Griffith University, Menzies Health Institute Queensland, National Centre for Neuroimmunology and Emerging Diseases, Southport, QLD 4222, Australia.
Email: s.marshall-gradisnik@griffith.edu.au

Creative Commons CC-BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 3.0 License (http://www.creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Results: Seventy-eight SNPs were identified in nicotinic and muscarinic acetylcholine receptor genes in the CFS/ME group, of which 35 were in mAChR3. The remaining SNPs were identified in nAChR delta (n = 12), nAChR alpha 9 (n = 5), TRPV2 (n = 7), TRPM3 (n = 4), TRPM4 (n = 1) mAChRM3 2 (n = 2), and mAChRM5 (n = 3) genes. Nine genotypes were identified from SNPs in TRPM3 (n = 1), TRPC6 (n = 1), mAChRM3 (n = 2), nAChR alpha 4 (n = 1), and nAChR beta 1 (n = 4) genes, and were located in introns and 3’ untranslated regions. Odds ratios for these specific genotypes ranged between 7.11 and 26.67 for CFS/ME compared with the non-fatigued control group.

Conclusion: This preliminary investigation identified a number of SNPs and genotypes in genes encoding TRP ion channels and AChRs from B cells in patients with CFS/ME. These may be involved in B cell functional changes, and suggest a role for Ca²⁺ dysregulation in AChR and TRP ion channel signalling in the pathomechanism of CFS/ME.

Keywords
Transient receptor potential ion channels, acetylcholine, chronic fatigue syndrome, muscarinic receptor, single nucleotide polymorphisms, B lymphocytes

Date received: 25 June 2016; accepted: 7 September 2016

Introduction
Acetylcholine (Ach) is a neuronal cholinergic neurotransmitter that transmits activation signals to receptors located in the central nervous system (CNS), skeletal and smooth muscle, preganglionic autonomic nerve fibres, postganglionic autonomic parasympathetic nerves, immune cells, and other tissues of the non-neuronal cholinergic system (NNCS).¹⁻⁴

Two types of membrane proteins bind Ach, muscarinic receptors (mAChRs) and nicotinic receptors (nAChRs), both of which have multiple isoforms. mAChRs are metabotropic receptors classified as M1 – M5, while nAChRs are ion channels that are typically heteromers of two subunits (selected from nine alpha and three beta subunits), with the exception of homomeric nicotinic alpha 7.⁵ The ratio of subtypes affects the signal conducting speed through the receptor.⁶ Importantly, one receptor subtype may impact on the receptor function of the other linked subtype.

In the NNCS, Ach binds AChRs on immune and other cell types. Ach is produced by lymphocytes expressing nAChRs that influence B lymphocyte function, including bone marrow development, B lymphocyte activation, and the autoantibody response.⁷⁻⁹ Within the NNCS, Ach also performs endocrine and paracrine functions in tissues such as smooth muscle, beta pancreatic cells, glial cells, lymphocytes, ocular lens cells, and brain vascular endothelium.¹⁰⁻¹⁴ These Ach functions are mediated by calcium signalling, which is particularly important for the activation of immune cell surface receptors.

mAChRs are inhibited by a type of calcium channel known as mammalian transient receptor potential (TRP) ion channels.¹⁵ These are Ca²⁺-permeable cation channels that act as an excitatory signal when opened to induce cell depolarisation and cause a Ca²⁺ influx, which plays a role in intracellular signalling pathways. TRPs are comprised of six main groups including TRPA (ankyrin), TRPC (canonical), TRPM (melastatin), TRPML (mucolipin), TRPP (polycystin), and TRPV (vanilloid).¹⁶ TRPs are present on almost all cell types, and their dysregulation has been associated with pathological conditions and disease.¹⁷⁻²²
Chronic fatigue syndrome (CFS) is also often referred to as myalgic encephalomyelitis (ME). To acknowledge previous work that refers to either terminology, this study refers to the hybrid acronym CFS/ME. CFS/ME is characterised by a distinct impairment in physical activity, debilitating fatigue accompanied by impairments in memory, cognition, and concentration, enhanced experience of pain, and dysregulation of gastrointestinal, cardiovascular, and immune systems.\textsuperscript{23–35} No diagnostic or screening test currently exists for this illness.

We previously identified single nucleotide polymorphisms (SNPs) in genes encoding receptors that require Ca\textsuperscript{2+} as an important component of their function. These include genes encoding TRP ion channels and AChRs, namely TRPM3, TRPA1, TRPC4,\textsuperscript{36} mAChRM3, nAChRs alpha 10, alpha 5, and alpha 2 in peripheral blood mononuclear cells (PBMCs) and isolated natural killer (NK) cells from CFS/ME patients.\textsuperscript{36,37,45} Additionally, we documented changes in intracellular Ca\textsuperscript{2+} mobilisation for TRPM3 from NK cells and B lymphocytes.\textsuperscript{38} These SNPs and their genotypes may alter the structures and functions of TRP ion channels and AChRs. A recent study reported that a subgroup of CFS/ME patients had muscarinic antibodies, and observed a modest positive response with reduced symptom presentation following anti-CD20 intervention.\textsuperscript{39} Given the important roles of Ca\textsuperscript{2+} and ACh signalling in B cell activation as well as the potential for antibody development, the present study aimed to identify SNPs and their genotypes for TRPs and AChRs from isolated B cells of CFS/ME patients.

**Patients and methods**

**Recruitment**

CFS/ME patients were defined in accordance with the 1994 CDC criteria for CFS/ME.\textsuperscript{40} A total of 11 CFS/ME patients and 11 non-fatigued controls with no medical history or symptoms of prolonged fatigue or illness of any kind were recruited from the National Centre for Neuroimmunology and Emerging Diseases (NCNED) research database.\textsuperscript{40} All participants attended NCNED to participate in research. Participants were excluded if they were pregnant or breastfeeding, or had a history of smoking or substance use. All participants provided signed consent and this study was approved by the Griffith University Research Ethics Committee (MSC22/12HREC). This study was approved by the Griffith University Human Research Ethics Committee (MSC22/12HREC).

**Sample preparation and measurements**

A total of 40 ml of blood was collected from the antecubital vein of participants into lithium heparinised and EDTA collection tubes between 09:00 h and 11:00 h. Routine blood samples were analysed within 6 h of collection for red blood cell counts, lymphocytes, granulocytes, and monocytes using an automated cell counter (ACT Differential Analyzer, Beckman Coulter, Miami, FL).

**B cell isolation**

PBMCs were isolated from 40 mL of whole blood using a previously described method.\textsuperscript{46} Briefly, PBMCs were isolated using a Ficoll-Paque density gradient (GE Healthcare, Uppsala, Sweden), then washed twice with phosphate-buffered saline (PBS) (Gibco-BRL, Gaithersburg, MD). Cells were then resuspended in autoMACs separation buffer (PBS with bovine serum albumin, EDTA, and 0.09% azide) (Miltenyi Biotec, Auburn, CA). Immunomagnetic negative selection of B cells was performed with B-cell isolation kit II (Miltenyi Biotec) according to the manufacturer’s instructions. Briefly, non-B cells such as T cells, NK cells, dendritic cells, monocytes, granulocytes,
and erythroid cells were indirectly magnetically labelled using a cocktail of biotin-conjugated antibodies against CD2, CD14, CD16, CD36, CD43, and CD235a (glycoporphin A). B cell isolation was then achieved following the depletion of magnetically labelled cells.

Untouched B cells fluorescently stained with anti-CD19-BV421 and anti-CD3-PerCP antibodies were measured using LSR Fortessa X-20 flow cytometry. Cell debris and dead cells were excluded from the analysis based on scatter signals. The mean purity was 85.66% ± 9.6% for non-fatigued controls and 76.5% ± 13.1% for CFS/ME patients, representing no significant difference between groups for levels of B lymphocytes.

**DNA extraction**

A total of 40 mL blood was collected into EDTA tubes for SNP analysis. Genomic DNA was extracted from whole blood samples using the Qiagen DNA blood mini-kit according to the manufacturer’s instructions (Qiagen, Venlo, Netherlands). SNP genotyping studies were performed as previously described.36,42

**SNP analysis**

A total of 661 SNPs were examined from 21 mammalian TRP ion channel genes (TRPA1, TRPC1, TRPC2, TRPC3, TRPC4, TRPC6, TRPC7, TRPM1, TRPM2, TRPM3, TRPM4, TRPM5, TRPM6, TRPM7, TRPM8, TRPV1, TRPV2, TRPV3, TRPV4, TRPV5, and TRPV6) and nine mammalian ACh receptor genes (muscarinic M1, M2, M3, M4, and M5, nicotinic alpha 2, 3, 5, 7, 9, and 10, beta 1, and 4, and epsilon) in B cell DNA using the MassARRAY iPLEX Gold Assay (a Matrix Assisted Laser Desorption Ionisation Time-of-Flight mass spectrometry platform; Sequenom Inc.).

Genomic DNA quality and quantity were assessed as previously described,44,48 including quantification using a Nanodrop spectrophotometer (Nanodrop). Approximately 2 μg of genomic DNA was then used to perform SNP analysis. MassARRAY was employed to discriminate alleles based on single-base extensions of an extension primer of known mass designed to attach next to the SNP site of interest. Custom multiplexed wells were designed in silico using Agena Bioscience’s Assay Design Suite, and built using custom synthesised oligonucleotides that were pooled for sample processing. The iPLEX Gold chemistry utilised two multiplexed oligo pools for each genotyping well. A multiplexed PCR pool was used to generate short amplicons that included all genomic markers of interest in that particular well. Following PCR and clean-up steps, a secondary PCR ‘extension’ step was undertaken with pools of extension primers that were designed to attach next to the SNP sites of interest. During the extension phase, a termination mix was added that enabled these extension primers to be extended by a single base only. Given the known molecular weight of the extension primer, allele discrimination could be measured using the peak heights of the unextended primer plus single-base extension possibilities for the SNP.

**TRP ion channel and AChR SNP assays**

Primers and extension primers were designed for each of the SNPs using Assay Designer software (Sequenom Inc.) according to the manufacturer’s instructions and as previously described.44,45 PCR conditions were as follows: 94°C for 2 min, 94°C for 30 s, 56°C for 30 s, and 72°C for 1 min. Amplification products were treated with shrimp alkaline phosphatase at 37°C for 40 min then 85°C for 5 min, and stored at 4°C. Extension primers were optimised to control the signal-to-noise ratio. This involved examining unextended primers (UEPs) on the
spectroCHIP array and evaluating them using Typer 4.0 software as low-mass UEP, medium-mass UEP, and high-mass UEP. iPLEX extension was performed using iPLEX Gold Buffer Plus, iPLEX termination mix, iPLEX enzyme, and primer mix at an initial denaturation of 94°C for 30 s, annealing at 52°C for 5 min, extension at 80°C for 5 min (five cycles of annealing and extension were performed, but the entire reaction involved 40 cycles), and an extension at 72°C for 3 min. Resin beads were used to rinse iPLEX Gold reaction products. MassARRAY was performed using the MassARRAY mass spectrometer, and generated data were analysed using TyperAnalyzer software.

**Statistical analysis**

Statistical analysis was performed using SPSS software version 22 (IBM). Experimental data were reported as means ± standard error of the mean (±SEM), while clinical data were reported as means ± standard deviation (±SD). Comparative assessments among participants (CFS/ME and non-fatigued controls) were performed using the analysis of variance test and the criterion for significance was set at \( P < 0.05 \).

The PLINK v1.07 (http://pngu.mgh.harvard.edu/purcell/plink/) whole genome analysis tool set was used to determine associations between CFS/ME patients and the non-fatigued control group. A two-column \( \chi^2 \) test was used to examine differences, with \( P < 0.05 \) taken to be significant. Further genotype analysis for differences between CFS/ME and the non-fatigued group was also completed according to a two-column \( \chi^2 \) test, and Yate’s correction factor was applied with significance at \( P < 0.05 \). Analyses were performed at the Australian Genome Research Facility Ltd. (Victoria, Australia).

**Results**

**Participants**

A total of 11 CFS/ME patients (mean age, 31.82 ± 5.50 years) were recruited, of whom 72.7% were females, together with 11 non-fatigued controls (mean age, 33.91 ± 5.06 years), of whom 63.6% were females. All

| Characteristic          | CFS/ME patients n = 11 | Non-fatigued controls n = 11 | P-value |
|-------------------------|------------------------|-----------------------------|---------|
| Gender (% female)       | 8 (72.7%)              | 7 (63.6%)                   | 0.497   |
| Mean age (years)        | 31.82 (5.50)           | 33.91 (5.06)                | 0.783   |
| Haemoglobin (g/L)       | 133 ± 2.70             | 134.70 ± 3.85               | 0.728   |
| Haematocrit (%)         | 0.36 ± 0.02            | 0.30 ± 0.02                 | 0.967   |
| Red cell count (×10¹²/L) | 4.40 ± 0.13            | 4.50 ± 0.11                 | 0.591   |
| Mean corpuscular volume (fL) | 89.56 ± 1.54       | 88.20 ± 0.61                | 0.406   |
| White cell count (×10⁹/L) | 7.09 ± 0.69            | 5.80 ± 0.32                 | 0.097   |
| Neutrophils (×10⁹/L)    | 4.15 ± 0.51            | 3.21 ± 0.21                 | 0.096   |
| Lymphocytes (×10⁹/L)    | 2.35 ± 0.23            | 2.13 ± 0.24                 | 0.549   |
| Monocytes (×10⁹/L)      | 0.36 ± 0.02            | 0.30 ± 0.02                 | 0.043   |
| Eosinophils (×10⁹/L)    | 0.19 ± 0.04            | 0.14 ± 0.03                 | 0.275   |
| Basophils (×10⁹/L)      | 0.03 ± 0.00            | 0.03 ± 0.01                 | 0.752   |
| Platelets (×10⁹/L)      | 241.56 ± 19.55         | 248.10 ± 18.35              | 0.810   |

CFS/ME, chronic fatigue syndrome/myalgic encephalomyelitis
Table 2. Frequency and distribution of SNPs in B cell genes for TRP ion channels and AChRs in chronic fatigue syndrome/myalgic encephalomyelitis patients and non-fatigued controls in rank order of significance.

| Gene     | CHR  | Ref SNP         | BP       | A1 F_A | F_U | A2 | \( \chi^2 \) | P-value | OR  |
|----------|------|-----------------|----------|--------|-----|----|-------------|---------|-----|
| CHRNA4   | 20   | rs11698563      | 63360932 | A      | 0.2885 | 0.7083 | C | 11.88 | 0 | 0.1669 |
| CHRNND   | 2    | rs11674608      | 2.33E+08 | G      | 0.34  | 0.7778 | C | 10.23 | 0 | 0.1472 |
| CHRNA9   | 4    | rs10009228      | 40354404 | A      | 0.1786 | 0.5   | G | 8.706 | 0 | 0.2174 |
| CHRM3    | 1    | rs1867264       | 2.40E+08 | A      | 0.28  | 0.6364 | T | 8.164 | 0 | 0.2222 |
| CHRNA9   | 4    | rs4861323       | 40353797 | G      | 0.1786 | 0.4583 | A | 6.792 | 0.01 | 0.2569 |
| CHRNA2   | 8    | rs2741341       | 27472768 | C      | 0.5179 | 0.2083 | T | 6.586 | 0.01 | 0.4081 |
| TRPC6    | 11   | rs11224816      | 1.02E+08 | T      | 0.5192 | 0.2083 | C | 6.511 | 0.01 | 4.104  |
| CHRNND   | 2    | rs12463989      | 2.33E+08 | C      | 0.3571 | 0.6667 | T | 6.503 | 0.01 | 0.2778 |
| CHRNND   | 2    | rs112001880     | 2.33E+08 | D      | 0.3571 | 0.6667 | I | 6.503 | 0.01 | 0.2778 |
| CHRNBD   | 15   | rs14402988      | 78635246 | G      | 0.01786 | 0.1667 T | 6.394 | 0.01 | 0.09091 |
| TRPV3    | 17   | rs4790519       | 3553440  | C      | 0.5556 | 0.25   | T | 6.242 | 0.01 | 3.75   |
| TRPM3    | 9    | rs1317103       | 70580786 | C      | 0.3519 | 0.6364 | T | 6.242 | 0.01 | 3.75   |
| CHRNND   | 2    | rs67583510      | 2.33E+08 | A      | 0.1852 | 0.4545 | G | 5.849 | 0.02 | 4.081  |
| CHRM3    | 1    | rs12093821      | 2.40E+08 | A      | 0.3269 | 0.6667 | G | 6.361 | 0.01 | 0.2429 |
| CHRM3    | 1    | rs1899616       | 2.40E+08 | A      | 0.3269 | 0.6667 | G | 6.361 | 0.01 | 0.2429 |
| CHRNBD   | 2    | rs112001880     | 2.33E+08 | D      | 0.3571 | 0.6667 | I | 6.503 | 0.01 | 0.2778 |
| CHRNBD   | 2    | rs12466358      | 2.33E+08 | G      | 0.1786 | 0.4167 | T | 5.079 | 0.02 | 0.3043 |
| CHRM5    | 15   | rs603152        | 34002435 | A      | 0.4643 | 0.2083 | C | 4.637 | 0.03 | 3.293  |
| CHRM3    | 1    | rs1155612       | 2.40E+08 | G      | 0.4   | 0.6667 | A | 4.616 | 0.03 | 0.3333 |
| CHRM2    | 7    | rs1424569       | 1.37E+08 | G      | 0.4   | 0.6667 | A | 4.616 | 0.03 | 0.3333 |
| TRPV2    | 17   | rs35400274      | 4900415  | A      | 0.07143 | 0.25  | G | 4.898 | 0.03 | 0.2308 |
| CHRM3    | 1    | rs16838637      | 2.40E+08 | G      | 0.3214 | 0.5833 | A | 4.802 | 0.03 | 0.3383 |
| CHRM3    | 1    | rs1867265       | 2.40E+08 | A      | 0.3214 | 0.5833 | A | 4.802 | 0.03 | 0.3383 |
| CHRM3    | 1    | rs7551001       | 2.40E+08 | G      | 0.3214 | 0.5833 | A | 4.802 | 0.03 | 0.3383 |
| CHRM3    | 1    | rs1155612       | 2.40E+08 | G      | 0.4   | 0.6667 | A | 4.616 | 0.03 | 0.3333 |
| CHRM2    | 7    | rs1424569       | 1.37E+08 | G      | 0.4   | 0.6667 | A | 4.616 | 0.03 | 0.3333 |
| TRPV2    | 17   | rs3514          | 4898298  | C      | 0.07407 | 0.25  | G | 4.601 | 0.03 | 0.24   |
| TRPV2    | 17   | rs12942540      | 4900777  | C      | 0.07407 | 0.25  | G | 4.601 | 0.03 | 0.24   |
| TRPM4    | 19   | rs11083963      | 49162082 | G      | 0.2826 | 0.5417 | A | 4.534 | 0.03 | 0.3333 |
| CHRM2    | 7    | rs1364403       | 1.37E+08 | T      | 0.4107 | 0.1667 | C | 4.475 | 0.03 | 3.485  |

(continued)
participants in both groups were of European
decent and were residents of Australia at the
time of blood collection. There were no
significant differences in white blood cell
counts between CFS/ME patients and the
non-fatigued control group. Table 1 outlines
participant characteristics. No significant dif-
ferences were identified between groups with
respect to routine pathology, except that the
number of monocytes was significantly higher
in the CFS/ME group than in healthy controls
\((P=0.04)\). However, the number of mono-
cytes among CFS/ME patients was within
the normal range, because any outliers were
excluded from analysis in this study. CFS/ME
patients were considered to have moderate
CFS, which was defined as a substantial
reduction in the activities that they performed
prior to their illness but the ability to continue
some activities outside the home.

| Table 2. Continued. |
|------------------------------------------------|
| **Gene** | **CHR** | **Ref SNP** | **BP** | **A1** | **F_A** | **F_U** | **A2** | \(\chi^2\) | **P-value** | **OR** |
|----------|---------|-------------|--------|--------|---------|---------|--------|----------|-------------|-------|
| TRPM3    | 9       | rs4620343   | 71121726 | T      | 0.4107  | 0.1667  | C      | 4.475    | 0.03       | 3.485 |
| CHRM3    | 1       | rs12743042  | 2.40E+08 | C      | 0.3704  | 0.6364  | T      | 4.473    | 0.03       | 0.3361 |
| CHRM3    | 1       | rs6688537   | 2.40E+08 | A      | 0.4074  | 0.6667  | C      | 4.47     | 0.03       | 0.3438 |
| CHRM5    | 15      | rs646950    | 33999458 | T      | 0.4615  | 0.2083  | C      | 4.461    | 0.03       | 3.257 |
| CHRM3    | 1       | rs2163546   | 2.40E+08 | G      | 0.5385  | 0.2727  | A      | 4.396    | 0.04       | 3.111 |
| CHRM3    | 1       | rs1544170   | 2.40E+08 | A      | 0.3704  | 0.625   | G      | 4.355    | 0.04       | 0.3529 |
| TRPM3    | 9       | rs3812532   | 70868677 | A      | 0.3704  | 0.625   | C      | 4.355    | 0.04       | 0.3529 |
| CHRN2    | 2       | rs2853457   | 2.33E+08 | A      | 0.5     | 0.25    | G      | 4.297    | 0.04       | 3     |
| CHRM3    | 1       | rs6429147   | 2.40E+08 | C      | 0.2963  | 0.5417  | G      | 4.283    | 0.04       | 0.3422 |
| CHRM3    | 1       | rs700643    | 2.40E+08 | C      | 0.2963  | 0.5417  | T      | 4.283    | 0.04       | 0.3563 |
| CHRM3    | 1       | rs10925941  | 2.40E+08 | A      | 0.2963  | 0.5417  | G      | 4.283    | 0.04       | 0.3563 |
| CHRM3    | 1       | rs576386    | 2.40E+08 | C      | 0.5192  | 0.25    | G      | 4.24     | 0.04       | 3.2    |
| CHRNA9   | 4       | rs10015231  | 40335548 | T      | 0.1964  | 0.4167  | C      | 4.209    | 0.04       | 0.3422 |
| TRPV2    | 17      | rs33970119  | 4901606  | A      | 0.03571 | 0.1667  | G      | 4.153    | 0.04       | 0.1852 |
| CHRM3    | 1       | rs1867263   | 2.40E+08 | A      | 0.3036  | 0.5417  | T      | 4.063    | 0.04       | 0.3688 |
| CHRM5    | 15      | rs511422    | 33990780 | C      | 0.4464  | 0.2083  | T      | 4.063    | 0.04       | 3.065 |
| TRPM3    | 9       | rs10780950  | 70578511 | T      | 0.2885  | 0.08333 | C      | 3.979    | 0.05       | 4.459 |
| TRPV2    | 17      | rs2075763   | 4899389  | T      | 0.03704 | 0.1667  | C      | 3.932    | 0.05       | 0.1923 |
| CHRM3    | 1       | rs685550    | 2.40E+08 | C      | 0.2222  | 0.04167 | A      | 3.9      | 0.05       | 6.571 |
| CHRM3    | 1       | rs6694220   | 2.40E+08 | G      | 0.4231  | 0.6667  | A      | 3.897    | 0.05       | 0.3667 |
| TRPV2    | 17      | rs1602006   | 16433973 | G      | 0.2692  | 0.5     | A      | 3.885    | 0.05       | 0.3684 |
| TRPV2    | 17      | rs7222754   | 16426430 | T      | 0.4423  | 0.2083  | C      | 3.863    | 0.05       | 3.014 |
| CHRN81   | 17      | rs3829603   | 7443722  | A      | 0.2593  | 0.5     | C      | 3.86     | 0.05       | 0.35 |
| CHRM3    | 1       | rs10754677  | 2.40E+08 | G      | 0.3846  | 0.625   | A      | 3.819    | 0.05       | 0.375 |
| CHRM3    | 1       | rs7513746   | 2.40E+08 | G      | 0.3889  | 0.625   | A      | 3.727    | 0.05       | 0.3818 |
| CHRM3    | 1       | rs10802795  | 2.40E+08 | C      | 0.3889  | 0.625   | T      | 3.727    | 0.05       | 0.3818 |
| CHRM3    | 1       | rs3738436   | 2.40E+08 | A      | 0.3889  | 0.625   | C      | 3.727    | 0.05       | 0.3818 |
| CHRM3    | 1       | rs7511970   | 2.40E+08 | A      | 0.3889  | 0.625   | G      | 3.727    | 0.05       | 0.3818 |
| CHRM3    | 1       | rs1155611   | 2.40E+08 | T      | 0.3889  | 0.625   | C      | 3.727    | 0.05       | 0.3818 |
| CHRM3    | 1       | rs1019882   | 2.40E+08 | G      | 0.3889  | 0.625   | A      | 3.727    | 0.05       | 0.3818 |
| CHRM3    | 1       | rs1416789   | 2.40E+08 | G      | 0.3889  | 0.625   | A      | 3.727    | 0.05       | 0.3818 |
| CHRM3    | 1       | rs10925964  | 2.40E+08 | A      | 0.3889  | 0.625   | T      | 3.727    | 0.05       | 0.3818 |
| CHRN81   | 17      | rs2302767   | 7447224  | C      | 0.2778  | 0.5     | T      | 3.725    | 0.05       | 0.3846 |

CHR, chromosome location; Ref SNP, reference SNP identification; \(\chi^2\), chi-squared for basic allelic test (one degree of
freedom); OR, odds ratio
Of the 661 SNPs identified in TRP ion channel and AChR genes from B cells, 77 were associated with genes encoding nAChRs and mAChRs in CFS/ME patients. These included 35 SNPs in the gene encoding mAChM3, while the remaining predominate SNPs were identified in genes encoding nAChR delta (n = 12), nAChR alpha 9 (n = 5), TRPV2 (n = 7), TRPM3 (n = 4), TRPM4 (n = 1), mAChRM2 (n = 2), and mAChRM5 (n = 3). Table 2 lists all SNPs in TRP ion channel and AChR genes in B cells of participants.

### Genotype analysis

Nine genotypes were identified from SNPs that showed significant differences in frequency between the CFS/ME group and the non-fatigued control group. These were: TRPM3 (n = 1), TRPC6 (n = 1), mAChRM3 (n = 2), nAChR alpha 4 (n = 1), and nAChR beta 1 (n = 4) (Table 3). Odds ratios (ORs) for specific genotypes for these SNPs ranged from 7.11 to 26.67 for the CFS/ME group compared with the non-fatigued control group.

### Discussion

The current investigation reports novel findings for AChR and TRP variants and genotypes in B cells from CFS/ME patients. These data are consistent with our previous findings for PBMCs and NK cells in CFS/ME patients.36,37,41

Intracellular Ca$^{2+}$ levels are substantially modulated by receptor-induced alterations, and are regulated by plasma membrane channels, intracellular receptor channels, non-selective cation channels, specific membrane transporters, and the cell membrane potential.20,46,47 Ca$^{2+}$ is critical for lymphocyte differentiation and function, as well as the regulation of antigen receptors, co-receptors, signal transduction, mitochondrial function, transcriptional factors, and gene expression.43–46

The immune system is dependent on cholinergic signalling because B and T cells express cholinergic receptors and regulate cytokines during inflammation48,49 and the immune response.50 Indeed, cholinergic signalling influences both B cell9 and T cell51 responses and has been found to initiate B cell autoimmunity.52 Of the cholinergic
receptor SNPs identified, mAChM3R featured prominently (45%) which is consistent with our previous findings for SNPs and their genotypes in NK cells. In our current investigation, we identified two SNP genotypes for mAChM3R. However, given the small sample number as well as taking into account our previous results for SNP genotypes from isolated NK cells and PBMCs, other genotypes for this receptor may be present in B cells of CFS/ME patients. A recent study reported a subgroup of CFS/ME patients with muscarinic antibodies (against mAChM3R), and in whom a modest positive response occurred with reduced symptom presentation following anti-CD20 intervention. Although patient genotypes were not reported in this subgroup analysis, our current findings, together with our previous genotype findings in isolated NK cells from a larger CFS/ME cohort, suggest that these genotype changes may play a role in B cell function. Moreover, the ubiquitous distribution of cholinergic receptors throughout the body suggests that anomalies in SNP genotypes and their heterodimer configuration and pattern may contribute to the various clinical symptoms of CFS/ME.

Our identification of SNPs in mAChRs and nAChRs from a diverse range of blood cells, such as PBMCs and isolated NK cells in larger cohorts of CFS/ME patients, suggests that cholinergic signalling may be impeded in this disorder. Muscarinic signalling was previously shown to play a role in gastrointestinal function, and antibodies to mAChM3Rs have been found to inhibit gastrointestinal motility and cholinergic neurotransmission. mACHM3Rs are present in the heart where they regulate intracellular phosphoinositide hydrolysis to improve cardiac contraction, haemodynamic function, and provide a protective effect against ischaemia. They are also located in the pancreas where they mediate acetylcholine control over insulin secretion and have other important regulatory functions.

Nicotinic signalling via nAChRs is widely distributed in organisms demonstrating the universal nature of cholinergic signalling. Muscle-type nAChRs, such as β1, are similar throughout the body. Our present study identified a high number of SNPs and genotypes in nAChRs, suggesting that the extent of SNP genotypes in cholinergic receptors may play a role in B cell function. Indeed, ACh functions as a paracrine/autocrine regulator of immune and other physiological functions. We demonstrate significant ORs for the genotypes of nAChR β1 SNPs rs3829603 (C/C) and rs4151134 (T/T), located in the 3’ untranslated region (UTR), ranging from 17.50 to 26.67 for the CFS/ME group. This is a binding site for regulatory proteins involved in the post-transcriptional control of gene expression. Binding to specific sites within the 3’ UTR may decrease the expression of various mRNAs either by inhibiting translation or directly causing degradation of the transcript. The agonist-binding site of nAChRs is located at the interface between adjacent subunits. An α subunit (α1, α2, α3, α4, α6, α7, or α9) comprises the positive side of the binding site, while the negative side is composed of α10, β2, β4, δ, γ, or ε subunits. α5, β1, and β3 subunits assemble in the receptor complex as a fifth subunit, not in the direct formation of the agonist-binding site, but forming an integral configuration for binding agonists and ligand selectivity. Given the number of SNP genotypes for nAChR β1 that were located in the 3’ UTR, the fifth subunit might be expected to alter ligand selectivity.

Various subunit combinations have previously been shown to give different nAChR subtypes that vary in their kinetic parameters, ion channel selectivity, ligand specificity, signalling pathways, and tissue functions. The high density of AChR distribution throughout the body means
that many tissues are likely to be affected following changes in AChR expression, with a potential loss of function of neuronal and non-neuronal cholinergic signalling pathways. This may explain the changes in B cell phenotypes of CFS/ME patients previously observed by us and others, we also separately reported a reduction in Ca\(^{2+}\) mobilisation into B cells via TRPM3 in association with receptor 3’ UTR SNP genotypes.

Cholinergic signalling in the brain is primarily focused on two main loci: the basal forebrain and the pedunculopontine area of the hindbrain. Acute vasoconstriction occurs after removal of the cholinergic parasympathetic input to forebrain cerebral arteries, indicating the critical importance of intact cholinergic signalling in the brain. Both nicotinic and muscarinic cholinergic signalling influence hippocampal synaptic plasticity and the processing of cholinergic-dependent higher cognitive functions. Cholinergic and glutamatergic signalling previously demonstrated interdependence in cortical glial cell function during sleep/wake studies. Moreover, the key CNS function of memory formation is Ca\(^{2+}\)-dependent through its association with cholinergic signaling, and is associated with long term potentiation in hippocampal synapses.

Although the present study is only a preliminary investigation, its small sample size is a limitation. Moreover, we only examined changes in patients with moderate CFS/ME, so future work should examine patients with severe CFS/ME who are housebound or bedridden. Nevertheless, our findings suggest that further investigations of mAChR and nAChR SNPs in a larger cohort of CFS/ME patients and healthy controls are warranted. We further suggest a comparison between a group meeting the diagnostic criteria for chronic fatigue alone, compared with those meeting criteria for CFS/ME, as an additional validation of the identified markers.

**Conclusion**

Our identification of SNP genotypes in cholinergic and TRP receptor genes in B cells, and previously in PBMCs and isolated NK cells, of CFS/ME patients suggests a potential contribution to systemic disease pathology including the immune, CNS, heart, gastrointestinal, and hormonal systems. The effects of these SNP genotypes on cholinergic signalling are likely to be particularly important in the CNS, peripheral nervous system, and autonomic nervous system. The functional effects of these genotypes and their combinations indicate that they may be contributing factors in the aetiology and clinical phenotypes of CFS/ME.

**Acknowledgements**

The authors would like to thank Dr Lavinia Gordon (Australian Genome Research Facility, Melbourne, Australia) for the bioinformatic SNP analysis.

**Authors’ contributions**

SMG and DRS designed and developed all experiments, and made final changes to the manuscript. PS, SJ, AC, and TH assisted in data analysis, and revised the manuscript.

**Declaration of conflicting interest**

The authors declare that there is no conflict of interest.

**Funding**

This study was supported by funding from the Stafford Fox Medical Research Foundation, the Alison Hunter Memorial Foundation, the Mason Foundation, and the Queensland Co-Investment...
Program. This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

References

1. Lendvai B and Vizi ES. Nonsynaptic chemical transmission through nicotinic acetylcholine receptors. Physiol Rev 2008; 88: 333–349.

2. Court JA, Martin-Ruiz C, Graham A, et al. Nicotinic receptors in human brain: topography and pathology. J Chem Neuroanat 2000; 20: 281–298.

3. Felder CC. Muscarinic acetylcholine receptors: signal transduction through multiple effectors. FASEB J 1995; 9: 619–625.

4. Brann MR, Ellis J, Jørgensen H, et al. Muscarinic acetylcholine receptor subtypes: localization and structure/function. Prog Brain Res 1993; 98: 121–127.

5. Shen JX and Yakel JL. Nicotinic acetylcholine receptor-mediated calcium signaling in the nervous system. Acta pharmacol Sin 2009; 30: 673–680.

6. d’Incamps BL and Ascher P. High affinity and low affinity heteromeric nicotinic acetylcholine receptors at central synapses. J Physiol 2014; 592: 4131–4136.

7. Skok M, Grailhe R and Changeux JP. Nicotinic receptors regulate B lymphocyte activation and immune response. Eur J Pharmacol 2005; 517: 246–251.

8. Fujii YX, Fujigaya H, Moriwaki Y, et al. Enhanced serum antigen-specific IgG1 and proinflammatory cytokine production in nicotinic acetylcholine receptor alpha7 subunit gene knockout mice. J Neuroimmunol 2007; 189: 69–74.

9. Koval L, Lykhmus O, Zhmak M, et al. Differential involvement of alpha4beta2, alpha7 and alpha9alpha10 nicotinic acetylcholine receptors in B lymphocyte activation in vitro. Int J Biochem Cell Biol 2011; 43: 516–524.

10. Beckmann J and Lips KS. The non-neuronal cholinergic system in health and disease. Pharmacology 2013; 92: 286–302.

11. Elhusseiny A and Hamel E. Muscarinic—but not nicotinic—acetylcholine receptors mediate a nitric oxide-dependent dilation in brain cortical arterioles: a possible role for the M5 receptor subtype. J Cereb Blood Flow Metab 2000; 20: 298–305.

12. Felder CC, Bymaster FP, Ward J, et al. Therapeutic opportunities for muscarinic receptors in the central nervous system. J Med Chem 2000; 43: 4333–4353.

13. Sharma G and Vijayaraghavan S. Nicotinic cholinergic signaling in hippocampal astrocytes involves calcium-induced calcium release from intracellular stores. Proc Natl Acad Sci USA 2001; 98: 4148–4153.

14. Wess J, Duttaroy A, Zhang W, et al. M1-M5 muscarinic receptor knockout mice as novel tools to study the physiological roles of the muscarinic cholinergic system. Receptors Channels 2003; 9: 279–290.

15. Badheka D, Borbiro I and Rohacs T. Transient receptor potential melastatin 3 is a phosphoinositide-dependent ion channel. J Gen Physiol 2015; 146: 65–77.

16. Nilius B, Owsianik G, Voets T, et al. Transient receptor potential cation channels in disease. Physiol Rev 2007; 87: 165–217.

17. Nilius B and Biø T. TRPV3: a ‘more than skinny’ channel. Exp Dermatol 2013; 22: 447–452.

18. Nilius B, Biø T and Owsianik G. TRPV3: time to decipher a poorly understood family member! J Physiol 2014; 592: 295–304.

19. Nilius B and Owsianik G. The transient receptor potential family of ion channels. Genome Biol 2011; 12: 218.

20. Nilius B and Szallasi A. Transient receptor potential channels as drug targets: from the science of basic research to the art of medicine. Pharmacol Rev 2014; 66: 676–814.

21. Nilius B and Voets T. The puzzle of TRPV4 channelopathies. EMBO Rep 2013; 14: 152–163.

22. Vennekens R, Menigoz A and Nilius B. TRPs in the brain. Rev Physiol Biochem Pharmacol 2012; 163: 27–64.

23. Aaron LA, Burke MM and Buchwald D. Overlapping conditions among patients with chronic fatigue syndrome, fibromyalgia, and
temporomandibular disorder. *Arch Intern Med* 2000; 160: 221–227.

24. Allen J, Murray A, Di Maria C, et al. Chronic fatigue syndrome and impaired peripheral pulse characteristics on orthostasis–a new potential diagnostic biomarker. *Physiol Meas* 2012; 33: 231–241.

25. Brenu EW, Ashton KJ, van Driel M, et al. Cytotoxic lymphocyte microRNAs as prospective biomarkers for chronic fatigue syndrome/myalgic encephalomyelitis. *J Affect Disord* 2012; 141: 261–269.

26. Brenu EW, Huth TK, Hardcastle SL, et al. Role of adaptive and innate immune cells in chronic fatigue syndrome/myalgic encephalomyelitis. *Int Immunol* 2014; 26: 233–242.

27. Brenu EW, Staines DR, Baskurt OK, et al. Immune and hemorheological changes in chronic fatigue syndrome. *J Transl Med* 2010; 8: 1.

28. Brenu EW, van Driel ML, Staines DR, et al. Longitudinal investigation of natural killer cells and cytokines in chronic fatigue syndrome/myalgic encephalomyelitis. *J Transl Med* 2012; 10: 88.

29. Brenu EW, van Driel ML, Staines DR, et al. Immunological abnormalities as potential biomarkers in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis. *J Transl Med* 2011; 9: 81.

30. DeLuca J, Johnson SK, Beldowicz D, et al. Neuropsychological impairments in chronic fatigue syndrome, multiple sclerosis, and depression. *J Neurol Neurosurg Psychiatry* 1995; 58: 38–43.

31. Hoad A, Spickett G, Elliott J, et al. Postural orthostatic tachycardia syndrome is an under-recognized condition in chronic fatigue syndrome. *QJM* 2008; 101: 961–965.

32. Klimas NG, Salvato FR, Morgan R, et al. Immunologic abnormalities in chronic fatigue syndrome. *J Clin Microbiol* 1990; 28: 1403–1410.

33. Lewis I, Pairman J, Spickett G, et al. Clinical characteristics of a novel subgroup of chronic fatigue syndrome patients with postural orthostatic tachycardia syndrome. *J Intern Med* 2013; 273: 501–510.

34. Medow MS and Stewart JM. The postural tachycardia syndrome. *Cardiol Rev* 2007; 15: 67–75.

35. Nisenbaum R, Reyes M, Mawle AC, et al. Factor analysis of unexplained severe fatigue and interrelated symptoms: overlap with criteria for chronic fatigue syndrome. *Am J Epidemiol* 1998; 148: 72–77.

36. Marshall-Gradisnik S, Smith P, Nilius B, et al. Examination of single nucleotide polymorphisms in acetylcholine receptors in chronic fatigue syndrome patients. *Immunol Immunogenet Insights* 2015; 7: 7.

37. Marshall-Gradisnik SM, Huth TK, Chacko A, et al. Natural killer cell cytotoxicity and single nucleotide polymorphisms in transient receptor potential ion channel and acetylcholine receptor genes of isolated natural killer cells in myalgic encephalomyelitis/chronic fatigue syndrome patients. *Clinical Application of Genetics (in review)* 2015. https://www.ncbi.nlm.nih.gov/pubmed/27099524.

38. Nguyen T, Staines D, Nilius B, et al. Characterisation of transient receptor potential melanostatin 3 ion channel and intracellular cell signalling in B and NK cells from patients with chronic fatigue syndrome. *Journal of translational medicine (in review)* 2015. https://www.ncbi.nlm.nih.gov/pubmed/27245705.

39. Loebel M, Grabowski P, Heidecke H, et al. Antibodies to β adrenergic and muscarinic cholinergic receptors in patients with chronic fatigue syndrome. *Brain Behav Immun* 2016; 52: 32–39.

40. Fukuda K, Straus SE, Hickie I, et al. The chronic fatigue syndrome: a comprehensive approach to its definition and study. International chronic fatigue syndrome study group. *Ann Intern Med* 1994; 121: 953–959.

41. https://www.ncbi.nlm.nih.gov/pubmed/26032326.

42. Marshall-Gradisnik SM, Smith P, Brenu EW, et al. Examination of single nucleotide polymorphisms (SNPs) in transient receptor potential (TRP) Ion channels in chronic fatigue syndrome patients. *Immunol Immunogenet Insights* 2015; 2015: 1–6.

43. Kang SW, Wahl MI, Chu J, et al. PKCbeta modulates antigen receptor signaling via
regulation of Btk membrane localization. *EMBO J* 2001; 20: 5692–5702.

44. Su TT, Guo B, Kawakami Y, et al. PKC-beta controls I kappa B kinase lipid raft recruitment and activation in response to BCR signaling. *Nat Immunol* 2002; 3: 780–786.

45. Li W, Llopis J, Whitney M, et al. Cell-permeant caged InsP3 ester shows that Ca$^{2+}$ spike frequency can optimize gene expression. *Nature* 1998; 392: 936–941.

46. Dolmetsch RE, Xu K and Lewis RS. Calcium oscillations increase the efficiency and specificity of gene expression. *Nature* 1998; 392: 933–936.

47. Negulescu PA, Shastri N and Cahalan MD. Intracellular calcium dependence of gene expression in single T lymphocytes. *Proc Natl Acad Sci U S A* 1994; 91: 2873–2877.

48. Kawashima K, Fujii T, Moriwaki Y, et al. Reconciling neuronally and nonneuronally derived acetylcholine in the regulation of immune function. *Ann N Y Acad Sci* 2012; 1261: 7–17.

49. Kawashima K, Fujii T, Moriwaki Y, et al. Critical roles of acetylcholine and the muscarinic and nicotinic acetylcholine receptors in the regulation of immune function. *Life Sci* 2012; 91: 986–991.

50. Wessler IK and Kirkpatrick CJ. Activation of muscarinic receptors by non-neuronal acetylcholine. *Handb Exp Pharmacol* 2012: 469–491.

51. Fuji T, Takada-Takatori Y and Kawashima K. Regulatory mechanisms of acetylcholine synthesis and release by T cells. *Life Sci* 2012; 91: 981–985.

52. Huijbers MG, Lipka AF, Plomp JJ, et al. Pathogenic immune mechanisms in the neuromuscular synapse: the role of specific antibody-binding epitopes in myasthenia gravis. *J Intern Med* 2014; 275: 12–26.

53. Tobin G, Giglio D and Lundgren O. Muscarinic receptor subtypes in the alimentary tract. *J Physiol Pharmacol* 2009; 60: 3–21.

54. Park K, Haberberger RV, Gordon TP, et al. Antibodies interfering with the type 3 muscarinic receptor pathway inhibit gastrointestinal motility and cholinergic neurotransmission in Sjogren’s syndrome. *Arthritis Rheum* 2011; 63: 1426–1434.

55. Wang H, Lu Y and Wang Z. Function of cardiac M3 receptors. *Auton Autacoid Pharmacol* 2007; 27: 1–11.

56. Wang S, Han HM, Jiang YN, et al. Activation of cardiac M3 muscarinic acetylcholine receptors has cardioprotective effects against ischaemia-induced arrhythmias. *Clin Exp Pharmacol Physiol* 2012; 39: 343–349.

57. Molina J, Rodriguez-Diaz R, Fachado A, et al. Control of insulin secretion by cholinergic signaling in the human pancreatic islet. *Diabetes* 2014; 63: 2714–2726.

58. Ruze de Azua I, Gautam D, Jain S, et al. Critical metabolic roles of β-cell M3 muscarinic acetylcholine receptors. *Life Sci* 2012; 91: 986–991.

59. Gautam D, Han SJ, Hamdan FF, et al. A critical role for beta cell M3 muscarinic acetylcholine receptors in regulating insulin release and blood glucose homeostasis in vivo. *Cell Metab* 2006; 3: 449–461.

60. Racké K, Juergens UR and Matthiesen S. Control by cholinergic mechanisms. *Eur J Pharmacol* 2006; 533: 57–68.

61. Kuersten S and Goodwin EB. The power of the 3’ UTR: translational control and development. *Nat Rev Genet* 2003; 4: 626–637.

62. Albuquerque EX, Pereira EF, Alkondon M, et al. Mammalian nicotinic acetylcholine receptors: from structure to function. *Physiol Rev* 2009; 89: 73–120.

63. Changeux JP. The nicotinic acetylcholine receptor: the founding father of the pentameric ligand-gated ion channel superfamily. *J Biol Chem* 2012; 287: 40207–40215.

64. Harcastle SL, Brenu E, Johnston S, et al. Analysis of the relationship between immune dysfunction and symptom severity in patients with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME). *J Clin Cell Immunol* 2014; 5: 4172.

65. Vijayaraghavan S and Sharma G. Editorial: Brain cholinergic mechanisms. *Front Synaptic Neurosci* 2015; 7: 14.
66. Boysen NC, Dragon DN and Talman WT. Parasympathetic tonic dilatory influences on cerebral vessels. *Auton Neurosci* 2009; 147: 101–104.

67. Gu Z and Yakel JL. Timing-dependent septal cholinergic induction of dynamic hippocampal synaptic plasticity. *Neuron* 2011; 71: 155–165.

68. Seigneur J, Kroeger D, Nita DA, et al. Cholinergic action on cortical glial cells in vivo. *Cereb Cortex* 2006; 16: 655–668.

69. Navarrete M, Perea G, Fernande de Sevilla D, et al. Astrocytes mediate in vivo cholinergic-induced synaptic plasticity. *PLoS-Biol* 2012; 10: e1001259.